Direct-acting antiviral regimens and HCV treatment failure and re-treatment in sub-Saharan Africa

Abstract

Today, most patients chronically infected with hepatitis C virus (HCV) can comfortably clear their infection after a 12-week course of direct-acting antivirals, which are easy to administer, well tolerated, and effective when administered as combination therapies.1 However, treatment failure after the use of direct-acting antivirals for HCV infection, which can be recurrent, is an emerging worldwide problem and a threat to the global elimination of chronic HCV infection. Predictors of failure of direct-acting antiviral treatment include HCV genotypes, subtypes, and viral adaptations.